The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of four new medicines in March and also weighed in on label expansions for existing therapies. The update included CHMP backing for subcutaneous Sarclisa from Sanofi and recommendations affecting oncology and other therapeutic areas. CHMP actions can accelerate European market access and can also set the stage for payer negotiations and national reimbursement timelines. The panel’s decisions also reflected boundaries on expanded indications, including a rebuffed label expansion for Vanda’s Hetlioz in Smith-Magenis syndrome. For biopharma, these CHMP votes remain a key read on European regulators’ appetite for new indications and alternative formulations.